Valeant received a joint takeover offer from Japan’s Takeda Pharmaceutical Co Ltd and TPG Capital Management LP this spring
Valeant Pharmaceuticals International Inc. (TSE:VRX) received a joint takeover offer from Japan’s Takeda Pharmaceutical Co Ltd and TPG Capital Management LP this spring that the Canadian drugmaker rejected, according to a source familiar with the matter.
The offer was made a few weeks before Joseph Papa took over as Valeant’s new chief executive in April last week, the source told Reuters.
The board wants to give Papa time to focus on running the company before thinking about a sale offer, the source said.
Read the full article at: ca.finance.yahoo.com
